EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 5

Turmeric (and curcumin) Curcuma longa L.

Also called: curcumin, Indian saffron, turmeric root, Curcuma domestica

Turmeric is a plant in the ginger family grown commercially in Southeast Asia and India. Its rhizome (underground stem) is used as a spice and in supplements. Curcumin, a major component, gives the spice its yellow color.

Category
Botanical
Part used
Rhizome
Strongest evidence
B Some positive trials
Reviewed
2026-10-28

Class 1 Well studied in people. A 2022 meta-analysis (BMC Complement Med Ther) pooled 15 RCTs (1,670 patients) of oral curcuminoids, the main constituents of turmeric extracts, used alone for knee osteoarthritis; trials combining them with other agents were excluded. [5]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

5 topics studied4 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Turmeric (and curcumin) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Turmeric (and curcumin), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Knee osteoarthritis pain and function (oral)BSeveral meta-analyses evaluated oral turmeric or curcumin; NCCIH calls the initial evidence positive but says higher-quality evidence is needed for definitive conclusions. [1]
Knee osteoarthritis pain (topical ointment)CNCCIH states it is unclear whether topical curcumin ointment affects knee osteoarthritis pain. [1]
Nonalcoholic fatty liver disease measuresCInitial research suggests oral turmeric or curcumin might improve some measures, but it is unclear which measures are consistently improved. [1]
Oral mucositis during cancer treatmentCInitial research suggests oral or mouthwash formulations might improve symptoms. [1]
Other conditionsCNCCIH states there isn't enough evidence to conclude whether oral turmeric or curcumin benefits other health conditions. [1]

Main constituents: Curcuminoids, including curcumin, to which turmeric's health activities are commonly attributed [1]; Curcumin makes up between 1% and 6% by dry weight of whole turmeric extracts [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Product labels suggest 100 to more than 1,000 mg daily, depending on the preparation; liver-injury case reports describe 500 to 1,000 mg daily. [2]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score A
    A: well known causeE: unlikely cause

    LiverTox likelihood score A (recently established as a well-documented cause of clinically apparent liver injury), chapter updated 2025-06-16.

    Details and sources
  • Pregnancy and breastfeeding
    NCCIH: the use of turmeric supplements during pregnancy may be unsafe …

    2 statements in the profile.

    Details and sources
  • Interactions with medicines
    5 listed

    Anticoagulants and antiplatelet drugs; Tacrolimus; CYP3A4 substrates; Paclitaxel; Camptothecin, mechlorethamine, doxorubicin, cyclophosphamide

    Details and sources
  • Cancer evaluations (IARC, NTP)
    1 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    6 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    EU (HMPC monograph, Revision 1, adopted 25 September 2018), traditional use for relief of digestive disturbances such as fullness, slow digestion and …

    Details and sources
  • Conventionally formulated oral turmeric or curcumin (not modified to enhance bioavailability) is likely safe in recommended amounts for up to 2 or 3 months. [1]
  • Liver damage has been reported with curcumin products formulated for increased bioavailability. Stop use and see a clinician if fatigue, nausea, poor appetite, dark urine or jaundice appear. [1]
  • LiverTox likelihood score A (well-documented cause of clinically apparent liver injury); hepatocellular injury, usually 1 to 4 months after starting. HLA-B*35:01 was found in over 70% of cases versus 10% to 15% of controls. [2]
  • Possible nausea, vomiting, acid reflux, stomach upset, diarrhea or constipation; topical curcumin can cause hives or itching. [1]
  • Supplements during pregnancy may be unsafe; little is known about amounts above food levels while breastfeeding. [1]
Interactions

Interactions

Turmeric (and curcumin)
From the table below 2 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Turmeric (and curcumin)
WithWhat happens
Anticoagulants and antiplatelet drugsPreclinical studies and a case report suggest turmeric can increase the risk of bleeding. [3]
TacrolimusAcute calcineurin-inhibitor kidney toxicity was reported in a liver-transplant patient using high amounts of turmeric. [3]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Oral curcumin products vary in how much curcumin they actually contain and often include other plant substances such as piperine from black pepper, which is added to raise curcumin bioavailability. [1]
  • Higher-absorption products use piperine or lipid nanoparticle delivery; these forms have been linked to several liver-injury cases. [2]
Regulation

Regulatory status

  • US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
  • EU: the HMPC adopted an EU herbal monograph; turmeric preparations have traditional use (based on long-standing use, not clinical trials) for relief of mild digestive problems in adults. [4]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Curcuminoids (curcumin, demethoxycurcumin and others), believed to be the active anti-inflammatory components and often collectively called curcumin; curcumin is 1% to 6% of whole turmeric extracts by dry weight Curcuminoids (polyphenols) [P1]
  • Volatile oils of the rhizome Volatile (essential) oil [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 6 entries naming turmeric, Curcuma longa or curcumin (earliest NDI 335 submitted 2005-06-01; most recent NDI 1039 submitted 2017-05-23). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. One of the six (NDI 387) names synthetic curcumin. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • NTP TR-427 (August 1993), turmeric oleoresin (79%–85% curcumin) in feed for 2 years: no evidence of carcinogenic activity in male F344/N rats; equivocal evidence in female rats (clitoral gland adenomas), in male B6C3F1 mice (hepatocellular adenoma; small-intestine carcinomas) and in female mice (hepatocellular adenomas). [P3]
  • Turmeric and curcumin do not appear in the IARC Monographs list of classifications (checked 2026-10-29). [P4]

Liver (NIH LiverTox)

  • LiverTox likelihood score A (recently established as a well-documented cause of clinically apparent liver injury), chapter updated 2025-06-16. Latency typically 1 to 4 months; hepatocellular pattern; HLA-B*35:01 found in over 70% of cases versus 10% to 15% of controls. LiverTox estimates the incidence at roughly 1:10,000 to 1:100,000 persons exposed and calls turmeric the most common cause of clinically apparent herbal-related liver injury in the United States. [P1]
  • Most cases are attributed to high-bioavailability curcumin forms, but cases have also been described with unadulterated ground turmeric powder and turmeric teas; re-exposure should be avoided because recurrence can be more severe. [P1]
  • EU monograph: because of possible stimulation of bile secretion, turmeric is not recommended in bile-duct obstruction, cholangitis, liver disease, gallstones or other biliary diseases. [P5]

Interactions with medicines

  • Anticoagulants and antiplatelet drugs: Preclinical data and case reports suggest an increased bleeding risk. [P6]
  • Tacrolimus: Turmeric pretreatment raised tacrolimus plasma levels in a murine model; a liver transplant patient who took high amounts of turmeric developed acute calcineurin-inhibitor nephrotoxicity. [P6]
  • CYP3A4 substrates: Curcumin inhibits CYP3A4 and may alter the metabolism of some drugs; conflicting data found no clinically relevant interaction with short-term use in healthy volunteers. [P6]
  • Paclitaxel: In 60 breast cancer patients taking 2 g/day turmeric, small changes in paclitaxel pharmacokinetic parameters were judged not clinically relevant. [P6]
  • Camptothecin, mechlorethamine, doxorubicin, cyclophosphamide: Turmeric inhibited drug-induced apoptosis of breast cancer cells in vitro, and dietary turmeric reduced cyclophosphamide-induced tumor regression in animals; clinical relevance is unknown. [P6]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • Black pepper (piperine): Piperine is added to raise curcumin absorption; LiverTox reports that high-bioavailability curcumin forms made with piperine or lipid nanoparticle delivery were linked to several cases of liver injury. [P1]

Adulteration and substitution

  • A scoping review of 48 publications (2,235 commercial turmeric samples, 2000–2025) found an overall adulteration rate of 20.0% (spices 20.4%; dietary and food supplements 22.0%); reported adulterants include artificial dyes, undeclared diluents and synthetic curcumin. [P7]
  • Of 356 turmeric samples from 23 cities in India, Pakistan, Sri Lanka and Nepal (2020–2021), 14% had detectable lead above 2 μg/g; samples with lead of 18 μg/g or more had lead-to-chromium molar ratios near 1:1, suggestive of lead chromate adulteration, with levels above 1,000 μg/g in some cities. [P8]
  • Synthetic curcuminoids can be blended to match natural ratios, so ratio tests alone cannot detect them; carbon-14 analysis is described as the most effective method, and carbon and hydrogen stable-isotope ratios (δ13C, δ2H) were proposed as an additional screen. [P9]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) for every dietary-ingredient component; an exemption may be requested by petition under 21 CFR 10.30. [P10]
  • Conformity with the European Pharmacopoeia monograph for turmeric rhizome (Ph. Eur. 2543) — The EU herbal monograph states that the material complies with Ph. Eur. monograph 2543. [P5]
  • Curcuminoid content assay — Commercial turmeric and curcumin preparations vary widely in curcuminoid content. [P1]
  • Lead and chromium (heavy metals) — Lead chromate adulteration of turmeric has been documented across South Asia. [P8]
  • Natural versus synthetic curcuminoids (carbon-14 or stable-isotope ratio analysis) — Synthetic curcumin is a reported adulterant that cannot be distinguished by curcuminoid ratios alone. [P9]

Supply and conservation

  • IUCN Red List: Data Deficient (DD), via GBIF species API, retrieved 2026-10-29. [P11]
  • India, Pakistan, Sri Lanka and Nepal together produce more than 80% of the world's turmeric. [P8]
  • LiverTox describes Curcuma longa as native to India and grown throughout Southern Asia and in Central America. [P1]

Absorption in people

  • In a single-dose escalation study in healthy volunteers (500 to 12,000 mg of a curcuminoid extract), no curcumin was detected in serum at 500 to 8,000 mg; low levels were detected in two subjects at 10,000 or 12,000 mg. [P12]
  • After 2 g curcumin alone in human volunteers, serum levels were either undetectable or very low. [P13]

Formulations studied to change absorption

Human data only.

  • Piperine 20 mg given with 2 g curcumin to healthy volunteers produced much higher serum concentrations from 0.25 to 1 h and increased bioavailability by 2000%. [P13]
  • LiverTox links high-bioavailability curcumin forms to liver-injury cases. [P1]

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU (HMPC monograph, Revision 1, adopted 25 September 2018), traditional use for relief of digestive disturbances such as fullness, slow digestion and flatulence, adults and elderly: powdered rhizome 0.5–1 g, 2–3 times daily; herbal tea 0.5–1.0 g in 150 ml boiling water, 2–3 times daily; tincture 1:10 (ethanol 70%) 0.5–1 ml, 3 times daily; dry extract DER 13–25:1 (ethanol 96%) 90–162 mg daily in 2–5 doses; dry extract DER 5.5–6.5:1 (ethanol 50%) 100–200 mg twice daily; tincture 1:5 (ethanol 70%) 10 ml once daily or 5 ml in 60 ml water 3 times daily. Not recommended under 18 years; consult a doctor if symptoms persist beyond 2 weeks. [P5]

Pregnancy and breastfeeding

  • NCCIH: the use of turmeric supplements during pregnancy may be unsafe; little is known about amounts above typical dietary levels during breastfeeding. [P14]
  • EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use is not recommended. [P5]

Sources for this profile

  1. NIH LiverTox (NIDDK). Turmeric (Last Update: 2025-06-16), 2025-06-16. ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. NTP. TR-427: Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (Major Component 79%-85% Curcumin) in F344/N Rats and B6C3F1 Mice (Feed Studies) (August 1993), 1993-08. ntp.niehs.nih.gov
  4. IARC Monographs. Agents Classified by the IARC Monographs: List of Classifications (accessed 2026-10-29), 2026-10-29. monographs.iarc.who.int
  5. European Medicines Agency, HMPC. European Union herbal monograph on Curcuma longa L., rhizoma, Revision 1 (EMA/HMPC/329755/2017; adopted 25 September 2018), 2018-09-25. ema.europa.eu
  6. Memorial Sloan Kettering Cancer Center. About Herbs: Turmeric (last updated June 9, 2026), 2026-06-09. mskcc.org
  7. Gafner S, et al. A scoping review of turmeric adulteration based on data from six continents. Pharm Biol 2026;64(1):87-107 (PMID 41452918), 2025-12-26. pubmed.ncbi.nlm.nih.gov
  8. Forsyth JE, et al. Evidence of turmeric adulteration with lead chromate across South Asia. Sci Total Environ 2024;949:175003 (PMID 39053552), 2024-11-01. pubmed.ncbi.nlm.nih.gov
  9. Perini M, et al. Stable Isotope Ratio Analysis for the Authentication of Natural Antioxidant Curcuminoids from Curcuma longa (Turmeric). Antioxidants 2023;12(2):498 (PMID 36830056), 2023-02-16. pubmed.ncbi.nlm.nih.gov
  10. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  11. GBIF species API: IUCN Red List category for Curcuma longa L., 2026-10-29. api.gbif.org
  12. Lao CD, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10 (PMID 16545122), 2006-03-17. pubmed.ncbi.nlm.nih.gov
  13. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64(4):353-6 (PMID 9619120), 1998-05. pubmed.ncbi.nlm.nih.gov
  14. NCCIH. Turmeric: Usefulness and Safety (Last Updated: April 2025), 2025-04. nccih.nih.gov
Sources

Sources

  1. NCCIH. Turmeric: Usefulness and Safety (Last Updated: 2025-04), 2025-04. nccih.nih.gov
  2. NIH LiverTox (NIDDK). Turmeric (Last Update: 2025-06-16), 2025-06-16. ncbi.nlm.nih.gov
  3. Memorial Sloan Kettering Cancer Center. About Herbs: Turmeric (Last Updated 2026-06-09), 2026-06-09. mskcc.org
  4. European Medicines Agency, HMPC. Curcumae longae rhizoma (turmeric) - herbal medicinal product, 2026-02-10. ema.europa.eu
  5. Feng J, et al. Efficacy and safety of curcuminoids alone in alleviating pain and dysfunction for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther 2022;22(1):276 (PMID 36261810), 2022-10-19. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.